

# **Data Sheet**

Product Name:	Chiauranib	
Cat. No.:	CS-0086815	
CAS No.:	1256349-48-0	Ť Ť
Molecular Formula:	C <sub>27</sub> H <sub>21</sub> N <sub>3</sub> O <sub>3</sub>	
Molecular Weight:	435.47	
Target:	Aurora Kinase; c-Fms; c-Kit; PDGFR; VEGFR	
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK	
Solubility:	DMSO : 62.5 mg/mL (143.52 mM; Need ultrasonic)	

### **BIOLOGICAL ACTIVITY:**

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC<sub>50</sub> values ranging from 1-9 nM. Chiauranib has strongly anticancer effects<sup>[1]</sup>. *In Vitro:* Chiauranib (CS2164; 3 µM; 24 hours) shows induction of G2/M cell cycle arrest and suppression of cell proliferation in tumor tissues through the inhibition of Aurora B-mediated H3 phosphorylation<sup>[1]</sup>.

In HUVEC and PDGFR $\beta$  phosphorylation in PDGFR $\beta$  overexpressed NIH3T3 cells, Chiauranib (CS2164; 0.03-3  $\mu$ M) displays antiangiogenic activities through suppression of VEGFR/PDGFR phosphorylation, inhibition of ligand-dependent cell proliferation and capillary tube formation, and prevention of vasculature formation in tumor tissues<sup>[1]</sup>.

. Chiauranib (CS2164) inhibits CSF-1R phosphorylation that leads to the suppression of ligand-stimulated monocyte-to-macrophage differentiation and reduces CSF-1R<sup>+</sup> cells in tumor tissues<sup>[1]</sup>. *In Vivo:* Chiauranib (CS2164; 0.5-40 mg/kg; oral administration; once daily; for 33 days or 43 days) treatment induces remarkable regression or complete inhibition of tumor growth at well-tolerated oral doses in several human tumor xenograft models. Chiauranib exhibits broad and potent in vivo anti-tumor activities<sup>[1]</sup>.

#### **References:**

[1]. You Zhou, et al. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci. 2017 Mar;108(3):469-477.

#### **CAIndexNames:**

1-Naphthalenecarboxamide, N-(2-aminophenyl)-6-[(7-methoxy-4-quinolinyl)oxy]-

## SMILES:

O=C(NC1=CC=CC=C1N)C2=C3C=CC(OC4=CC=NC5=CC(OC)=CC=C54)=CC3=CC=C2

## Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

E-mail: sales@ChemScene.com